πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9814695

Ophthalmic solutions for glaucoma and conjunctivitis treatment

AXIM BIOTECHNOLOGIES. INC. Β· Granted Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9809649

Cachexia treatment

XBIOTECH INC. Β· Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9808460

Controlled release auris sensory cell modulator compositions and methods for the treatment

The Regents of the University of California Β· Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9808458

Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9801865

Materials and methods for diagnosis, prevention and/or treatment of stress disorders and c

The United States of America as represented by the Department of Veteran Affairs Β· Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9801894

Steroid compound for use in the treatment of hepatic encephalopathy

Umecrine Cognition AB Β· Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9801887

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9790215

Pyridazinone compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC Β· Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9783529

Pyridazinone compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC Β· Granted Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9782347

Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal

The Regents of the University of California Β· Granted Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9775889

Methods of treatment of cellulite

HALOZYME, INC. Β· Granted Tue Oct 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9771428

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9771327

Compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC Β· Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9770427

Antiviral treatments

BioCryst Pharmaceuticals, Inc. Β· Granted Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765340

RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765337

Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatm

The Regents of the University of California Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765142

TEM8 antibodies and their use in treatment and detection of tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9765053

Methods of treatment using selective 5-HT2A inverse agonists

ACADIA Pharmaceuticals Inc. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9764001

Target for diagnosis and treatment of diabetes and cardiovascular diseases

The Regents of the University of California Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9763974

Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with ele

GALECTIN THERAPEUTICS, INC. Β· Granted Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9757407

Treatment of viral infections by modulation of host cell metabolic pathways

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9757366

Methods for the treatment of parkinson's disease psychosis using pimavanserin

ACADIA Pharmaceuticals Inc. Β· Granted Tue Sep 12 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9752147

RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9750724

Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

MEREO BIOPHARMA 2 LIMITED Β· Granted Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted